You are here: Industry Insights > Daiichi Sankyo

News List

AZ, Daiichi Sankyo’s Enhertu wins US approval for HER2-positive gastric cancer pharmatimes
January 19, 2021
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval in the US for the treatment of locally advanced/metastatic HER2-positive gastric or gastroesophageal junction (GEJ) ...
Enhertu scores ‘impressive’ new data in HER2 breast cancer pharmatimes
December 11, 2020
AstraZeneca (AZ) and Daiichi Sankyo have reported updated results from a phase II trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy in patients with HER2-positive metastatic breast cancer.
Half of top 20 global innovative pharma companies MCap reported positive growth in Q3 2020- GlobalData expresspharma
November 27, 2020
Half of the companies in a ranking of top 20 global innovative pharmaceutical firms by data and analytics company GlobalData reported positive market capitalization (MCap) growth in Q3, with Pfizer and Daiichi Sankyo Co reporting double-digit percentage..
American Regent Announces CEO Transition for 2021 americanpharmaceuticalreview
November 25, 2020
American Regent, a Daiichi Sankyo Group company, announced Ken Keller, currently serving as the company's President and CEO, is transitioning to a new role as the Global Head of Oncology Business at Daiichi Sankyo, effective April 1, 2021.
Daiichi Sankyo initiates phase 2 study of patritumab deruxtecan in advanced colorectal cancer pharmaceutical-business-review
September 17, 2020
Daiichi Sankyo Company announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), in patients with advanced or metastatic colorectal cancer who are ...
Rain Therapeutics Licenses MDM2 Inhibitor from Daiichi Sankyo contractpharma
September 03, 2020
DS-3032 has been evaluated in clinical trials for solid tumors and hematologic malignancies.
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC pharmaceutical-business-review
August 11, 2020
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402) ...
AstraZeneca, Daiichi Sankyo Announce Collaboration for New Antibody Drug Conjugate americanpharmaceuticalreview
August 04, 2020
AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential ...
Daiichi Sankyo, AstraZeneca Enter New $6B Global ADC Alliance contractpharma
August 03, 2020
To jointly develop and commercialize DS-1062, a TROP2 directed DXd antibody drug conjugate in Phase I for non-small cell lung cancer and breast cancer.
AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo pharmaceutical-technology
July 28, 2020
AstraZeneca has signed a new agreement to develop and commercialise Japanese company Daiichi Sankyo’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), DS-1062, globally for various tumour types.

Previous page 1 2 3 4 5 6 7 8 Next page